Director of the Office of Antimicrobial Products at the FDA, Edward Cox, said, "Rapivab is the third neuraminidase inhibitor
approved by the FDA to treat flu infection, but the first approved as an intravenous formulation.
Oseltamivir, the neuraminidase inhibitor
, and amantadine, an M2 ion channel inhibitor, face 90% and 100% resistance respectively, in some areas.
susceptibility testing in human influenza viruses: a laboratory surveillance perspective.
So basically all that physicians had available early on were the oral neuraminidase inhibitor
oseltamivir (Tamiflu) and the inhalation-only formulation of zanamivir (Relenza), another neuraminidase inhibitor
Tamiflu is an oral neuraminidase inhibitor
that is active against all strains of influenza A and B tested.
Writing in the British Medical Journal (BMJ), they said just one mutation could lead to a flu strain resistant to neuraminidase inhibitors
or ion channel inhibitors.
has signed an agreement with Green Cross Corporation, South Korea for the development and commercialization in Korea of peramivir, BioCryst's potent influenza neuraminidase inhibitor
Peramivir is a neuraminidase inhibitor
, as are the currently used drugs Tamiflu and Relenza; however, its manufacturer claims that this drug will be easier and cheaper to produce than available drugs.
Zanamivir, like oseltamivir, is a neuraminidase inhibitor
that is effective against both influenza A and influenza B.
The drug - at this stage known only as a neuraminidase inhibitor
- acts by blocking the spread of the virus once it has invaded the body.
A neuraminidase inhibitor
is a true antiviral agent in that it works on all strains by affecting how the virus behaves.
BioCryst currently has two late-stage development programs: peramivir, a viral neuraminidase inhibitor
for the treatment of influenza, and ulodesine, a purine nucleoside phosphorylase (PNP) inhibitor for the treatment of gout.
InavirA by Daiichi Sankyo is a long-acting neuraminidase inhibitor
developed and manufactured in Japan.
50]s (concentration of neuraminidase inhibitor
required to reduce enzyme activity by 50%) with all 4 NAIs, similar to results for the drug-sensitive seasonal influenza A viruses used as controls (Table 1).
In the six trials totaling nearly 2,000 subjects in which administration of antibiotics was an end point, treatment with a neuraminidase inhibitor
conferred a 23% reduction in the use of antibiotic therapy, he continued.